This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome (NCT02658175), a non-randomized phase 3 study. The primary outcome is Mean Percent Change From Baseline in Fasting Triglyceride (TG).
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT02658175 |
| Phase | Phase 3 |
| Condition | Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency, Hyperlipoproteinemia Type 1 |
| Allocation | Non-Randomized |
| Design model | Parallel |
| Masking | None (open label) |
| Enrollment | 68 |
| Arms in the primary outcome | n/a |
| Lead sponsor | Akcea Therapeutics |
| Results posted | Yes |
2. Clinical Question
Population
Participants with familial chylomicronemia syndrome, including people with lipoprotein lipase deficiency or hyperlipoproteinemia type 1. The registry describes a treatment-naïve group and participants who rolled over after receiving volanesorsen in earlier studies.
Intervention
Volanesorsen administered by subcutaneous injection in an open-label study. The registry describes a planned regimen of 300 mg once weekly for Weeks 1-52, with dose adjustment or reduction permitted for rollover participants based on monitoring.
Comparator
There was no randomized control group in this non-randomized study. The registry describes parallel groups, but these are not a like-for-like control comparison: participants in the rollover groups had previously received volanesorsen, and the treatment-naïve group included participants from an earlier study.
Primary question
What was the mean percent change from baseline in fasting triglyceride at Months 3, 6, and 12? The registry identifies this as the primary endpoint but does not report numerical endpoint results in the registry record.
This is a descriptive question about change over time among participants receiving study drug, not a randomized estimate of the difference between volanesorsen and a concurrent untreated group. The registry lists familial chylomicronemia syndrome and two related conditions. It does not provide a numerical estimate of the primary endpoint, an uncertainty interval, or an inferential test result in the registry record.
3. Trial Design
The registry describes a Phase 3, open-label, non-randomized, parallel study sponsored by Akcea Therapeutics. It lists enrollment of 68 participants and a completed status. The study start was 2015-12-23, and primary completion was 2020-01-15. The intervention was volanesorsen, administered subcutaneously.
Three groups are described: Treatment-naïve Group, CS6-Volanesorsen, and CS16-Volanesorsen. The treatment-naïve group included participants in the new study and participants who had received placebo in index studies. The other groups included participants rolling over from the CS6 and CS16 index studies after receiving volanesorsen. The registry describes weekly dosing of 300 mg for Weeks 1-52. Dose adjustment or dose reduction was allowed for rollover participants based on monitoring; further details of the monitoring rules are not reported in the registry record.
Because assignment was not randomized and there was no like-for-like control comparison, differences between groups cannot be interpreted as if they arose from randomized treatment allocation. Participants entered the groups with different treatment histories, and the registry does not describe a concurrent control group. The open-label design also means that treatment and study participation were not masked. These features are important when interpreting any changes over time: the registry describes them as observations under the study regimen, not as a controlled estimate of treatment effect.
The registry lists an overall enrollment of 68. The at-risk counts in the safety record are 51 in Treatment-naïve Group, 14 in CS6-Volanesorsen, and 3 in CS16-Volanesorsen. These safety counts describe participants at risk for the listed safety outcomes; they do not replace the endpoint-specific number analyzed, which may vary by time point. The detailed protocol, reasons for group sizes, and any sample-size justification are not reported in the registry record.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Before assignment: A total of 68 participants were enrolled into this study.
Treatment Period: Weeks 1 to 52
| Stage | Treatment-naïve Group | CS6-Volanesorsen | CS16-Volanesorsen |
|---|---|---|---|
| STARTED | 51 | 14 | 3 |
| COMPLETED | 36 | 7 | 3 |
| NOT COMPLETED | 15 | 7 | 0 |
Reasons for not completing this period:
| Reason | Treatment-naïve Group | CS6-Volanesorsen | CS16-Volanesorsen |
|---|---|---|---|
| Investigator Judgment | 1 | 0 | 0 |
| Voluntary Withdrawal | 6 | 2 | 0 |
| Adverse Event or Serious Adverse Event (SAE) | 8 | 5 | 0 |
1st Extended Treatment: Weeks 53 to 104
| Stage | Treatment-naïve Group | CS6-Volanesorsen | CS16-Volanesorsen |
|---|---|---|---|
| STARTED | 36 | 7 | 3 |
| COMPLETED | 15 | 5 | 1 |
| NOT COMPLETED | 21 | 2 | 2 |
Reasons for not completing this period:
| Reason | Treatment-naïve Group | CS6-Volanesorsen | CS16-Volanesorsen |
|---|---|---|---|
| Investigator Judgment | 1 | 0 | 0 |
| Voluntary Withdrawal | 4 | 0 | 1 |
| Adverse Event or SAE | 7 | 0 | 0 |
| Other | 1 | 0 | 1 |
| Transferred to Early Access Programs | 8 | 2 | 0 |
2nd Extended Treatment: Weeks 105 to156
| Stage | Treatment-naïve Group | CS6-Volanesorsen | CS16-Volanesorsen |
|---|---|---|---|
| STARTED | 1 | 0 | 1 |
| COMPLETED | 0 | 0 | 0 |
| NOT COMPLETED | 1 | 0 | 1 |
Reasons for not completing this period:
| Reason | Treatment-naïve Group | CS6-Volanesorsen | CS16-Volanesorsen |
|---|---|---|---|
| Adverse Event or SAE | 0 | 0 | 1 |
| Transferred to Commercial Treatment | 1 | 0 | 0 |
Analysis population for the primary outcome, as defined in the registry: FAS included all participants who were enrolled and received at least one dose of study drug and who had an open-label study baseline TG assessment. Here, "number analyzed" signifies participants evaluable for this outcome measure at specified time points.
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
Population: Full Analysis Set (FAS) included all participants who were enrolled and received at least one dose of study drug and who had an open-label study baseline triglyceride (TG) assessment.
| Characteristic | Unit | Treatment-naïve Group | CS6-Volanesorsen | CS16-Volanesorsen | Total |
|---|---|---|---|---|---|
| Participants analysed | 51 | 14 | 3 | 68 | |
| Age, Continuous | years | 47 (SD 14) | 48 (SD 14) | 48 (SD 11) | 47 (SD 13) |
| Sex: Female, Male: Female | Participants | 34 | 7 | 2 | 43 |
| Sex: Female, Male: Male | Participants | 17 | 7 | 1 | 25 |
| Ethnicity (NIH/OMB): Hispanic or Latino | Participants | 2 | 0 | 0 | 2 |
| Ethnicity (NIH/OMB): Not Hispanic or Latino | Participants | 49 | 14 | 3 | 66 |
| Ethnicity (NIH/OMB): Unknown or Not Reported | Participants | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized: Race – White | Participants | 39 | 11 | 3 | 53 |
| Race/Ethnicity, Customized: Race – Asian | Participants | 11 | 3 | 0 | 14 |
| Race/Ethnicity, Customized: Race – Other Race | Participants | 1 | 0 | 0 | 1 |
| Fasting Triglyceride (TG) | milligrams per decilitre (mg/dL) | 2341 (SD 1193) | 1523 (SD 946) | 2081 (SD 706) | 2161 (SD 1166) |
6. Primary Endpoint
The registry lists the primary outcome as Mean Percent Change From Baseline in Fasting Triglyceride (TG), measured over Baseline and Months 3, 6, and 12.
| Element | Registry entry |
|---|---|
| Result type | Mean |
| Measure of spread | Standard Deviation |
| Unit | percent change |
| Endpoint classification | Continuous Endpoint |
The primary endpoint is mean percent change from baseline in fasting triglyceride (TG), assessed at Baseline and Months 3, 6, and 12. It is a continuous outcome: the registry identifies the reported summary as a mean with standard deviation. The endpoint expresses change relative to each participant’s defined baseline, then summarizes those changes across the participants evaluable at each time point. No numerical mean or standard deviation for the endpoint is reported in the registry record.
Baseline was defined differently according to prior study history. For the treatment-naïve group, it was the average of the open-label Day 1 pre-dose assessment and the last measurement before open-label Day 1. For the CS6-Volanesorsen and CS16-Volanesorsen groups, it was the average of the index-study Day 1 pre-dose assessment and the last measurement before that index-study Day 1.
The Month 3 value was defined as the average of the Week 12 (Day 78) and Week 13 (Day 85) fasting assessments. Month 6 used the average of the Week 25 (Day 169) and Week 26 (Day 176) assessments. Month 12 used the average of the Week 50 (Day 344) and Week 52 (Day 358) assessments. Averaging nearby fasting assessments is the registry’s stated approach for defining those endpoint time points; it does not, by itself, indicate how missing assessments were handled.
In general, a continuous endpoint can describe both the direction and magnitude of change, while its variability describes how dispersed individual changes are around the group mean. Fasting TG is the outcome selected in this study; the registry does not state a fuller rationale for choosing it as the primary endpoint.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The registry identifies mean percent change from baseline in fasting TG as the primary endpoint and specifies assessment at Months 3, 6, and 12. However, numerical endpoint estimates are not reported in the registry record. There is therefore no posted mean change, standard deviation, confidence interval, or test result from which to describe the observed size or precision of the primary outcome. The endpoint definition alone does not establish whether the group mean increased or decreased.
The study design also limits the kind of interpretation that can be made. This was a non-randomized, open-label study with parallel groups, and the registry explicitly notes that the arms are not a like-for-like control comparison. The treatment-naïve group and rollover groups differed in prior treatment history. A comparison among those groups would not isolate the effect of volanesorsen from differences in who entered each group, what treatment they had previously received, or other differences not described in the registry record.
Within-group change over time, if numerical estimates were available, would describe what was observed among evaluable participants during follow-up. Without a concurrent randomized comparator, it would not by itself show what would have happened to the same participants without volanesorsen. This is a general distinction between describing change and estimating a causal treatment effect. The registry record does not report adjusted between-group analyses or other inferential analyses; the number of analyses recorded is 0.
The endpoint uses a mean and standard deviation. In general, a mean describes the center of a set of continuous values, while a standard deviation describes their spread. Neither statistic alone communicates precision of the mean; a confidence interval would provide an interval estimate of that precision. No confidence interval for the primary endpoint is reported in the registry record. The absence of a posted estimate means that the magnitude and uncertainty of change cannot be assessed from this record.
The registry lists safety counts separately for the three groups. Serious adverse events affected 13 of 51 participants in Treatment-naïve Group, 2 of 14 in CS6-Volanesorsen, and 2 of 3 in CS16-Volanesorsen. These are descriptive counts, not randomized comparisons. The small at-risk count in CS16-Volanesorsen makes its count particularly sensitive to the experience of individual participants. The registry reports 0 deaths in each group. These safety observations do not supply the missing primary endpoint estimates and should not be treated as evidence about comparative efficacy.
Any sample-size illustration based on an observed effect would be a planning exercise, not an estimate of observed power. The record describes a planning approach using a two-sided significance level of 0.05, equal allocation, and a normal approximation, with the target effect defined as a stated fraction of the observed effect. But no observed primary effect or resulting participant targets are reported in the registry record. Such planning numbers cannot substitute for the endpoint estimates or their uncertainty.
9. Statistical Methods Explained
What does the mean summarize?
The primary outcome is continuous and the registry specifies a mean with standard deviation. As a general statistical explanation, the mean is the arithmetic average of the observed values in an analysis group. It gives a compact description of the group’s central value but can be influenced by unusually large or small observations. The standard deviation describes how much the individual observations vary around the mean. It is not the same as the uncertainty in the estimated mean, and it does not show the full shape of the data distribution.
The registry’s endpoint is percent change from baseline, so the summarized values are changes relative to a defined starting point rather than raw TG levels alone. The endpoint description gives specific baseline rules for participants new to the open-label study and participants who rolled over from prior studies. The registry does not give the numerical baseline or follow-up values in the record, so the amount of change cannot be reconstructed.
How are the follow-up time points defined?
The protocol description identifies Month 3, Month 6, and Month 12 assessment points. For each, the registry defines the endpoint value as an average of two nearby fasting assessments: Week 12 (Day 78) and Week 13 (Day 85) for Month 3; Week 25 (Day 169) and Week 26 (Day 176) for Month 6; and Week 50 (Day 344) and Week 52 (Day 358) for Month 12. These are endpoint construction rules, not evidence that every participant contributed assessments at each visit.
The registry states that “number analyzed” means participants evaluable for this outcome measure at the specified time points. The endpoint-specific numbers analyzed at each visit are not reported in the registry record. Without those counts, readers cannot determine from the record how the size of the analyzed set changed over time.
What does a confidence interval add?
As a general statistical explanation, a confidence interval gives a range of values compatible with the data and analysis procedure, and indicates the precision of an estimate. A narrow interval generally signals greater precision than a wide interval, while neither interval width nor the point estimate alone resolves biases arising from study design. Confidence intervals for the primary endpoint are not reported in the registry record. No test statistic or p-value for that endpoint is reported either.
The distinction between spread and precision matters. A standard deviation describes variation among participants; a confidence interval for a mean describes uncertainty about the mean estimate. The registry identifies standard deviation as the dispersion measure, but does not report its numerical value for this outcome. It is therefore not possible to assess either the observed variability or the precision of the mean from the endpoint results in this record.
Why does the design affect interpretation?
As a general statistical principle, random allocation helps balance measured and unmeasured participant characteristics across treatment groups, on average. This study was non-randomized, and its groups reflect different treatment histories. The registry also identifies the arms as not being a like-for-like control comparison. Consequently, a difference between group summaries would not automatically be an unbiased estimate of a treatment effect. The record does not describe an adjusted analysis that attempts to address such differences.
Open-label treatment means masking was absent. In general, knowledge of treatment can affect behavior, reporting, or other aspects of study conduct. The endpoint is a fasting laboratory measure, but the registry does not describe methods used to limit possible influence from open-label conduct. This is not a claim that such influence occurred; it identifies a design consideration for interpretation.
What is over-dispersion?
As a general concept, over-dispersion occurs when observed variability is greater than a statistical model assumes. It is especially relevant to outcomes such as counts or rates when a model’s variance assumptions are too restrictive. The primary endpoint is continuous and summarized as a mean and standard deviation, and the registry does not describe an over-dispersion model for it. No model specification for the primary analysis is reported in the registry record, so it would be inappropriate to infer which assumptions or adjustments were used.
What does the planning approach mean?
The registry describes a planning illustration based on an observed effect, with a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. The effect to detect is described as a stated fraction of the observed effect. These are planning assumptions, not the trial’s reported design justification, and the record does not report the protocol’s sample-size justification. Since the observed endpoint effect and calculated participant targets are not reported in the registry record, no numerical planning target can be interpreted from the available information.
In general, sample-size calculations estimate how many participants may be needed under stated assumptions to detect a specified effect with a chosen probability. They are prospective planning tools, not observed power. A calculation based on an effect observed after a study is complete is particularly dependent on that estimated effect and should not be presented as a measure of the study’s achieved evidential strength. No calculated participant targets for this endpoint are reported in the registry record.
What analyses are available?
The registry lists 0 analyses. It identifies the endpoint, population description, time points, and summary type, but does not report the statistical model, handling of repeated measurements, covariate adjustment, or inferential testing procedure. Those methods are not reported in the registry record. The endpoint definitions can be described, but the analysis cannot be independently reproduced from numerical results that are absent from the registry entry.
10. Multiplicity, Missing Data and Analysis Populations
The primary endpoint has multiple stated follow-up times: Months 3, 6, and 12. When several time points or outcomes are tested, the chance of at least one false-positive finding can increase if no multiplicity strategy is used. As a general statistical principle, a plan may address this by defining a primary time point, adjusting significance thresholds, or specifying a testing hierarchy. The registry does not report a multiplicity strategy, a primary time-point hierarchy, or inferential results for these time points; these details are not reported in the registry record.
The registry lists 2 outcome measures and 0 analyses. It names the primary endpoint and its assessment schedule, but does not report numerical estimates, confidence intervals, p-values, or the analysis procedure. It is therefore not possible to establish from the registry record whether any multiplicity adjustment was applied or how results across outcomes and visits were interpreted.
The outcome population is described as the FAS: participants enrolled, receiving at least one dose of study drug, and having an open-label study baseline TG assessment. The registry further says that the number analyzed refers to participants evaluable for the outcome at the specified time point. This definition allows the analyzed group to vary by visit, but the numbers analyzed at each visit are not reported in the registry record.
Missing-data handling is also not reported in the registry record. The endpoint description specifies how paired visit measurements are averaged, but does not state what happened if one or both measurements were missing, if a participant discontinued, or if an assessment was unavailable. No imputation method, sensitivity analysis, or assumption about missingness is described. These omissions make it difficult to assess how incomplete follow-up could affect the reported endpoint, even if point estimates were available.
11. Safety Results
The registry reports serious adverse events as affected participants divided by participants at risk.
| Arm | Participants with serious adverse events | Participants at risk | Percentage |
|---|---|---|---|
| Treatment-naïve Group | 13 | 51 | 25.5% |
| CS6-Volanesorsen | 2 | 14 | 14.3% |
| CS16-Volanesorsen | 2 | 3 | 66.7% |
Deaths
| Arm | Deaths (participants affected of at risk) |
|---|---|
| Treatment-naïve Group | 0 of 51 |
| CS6-Volanesorsen | 0 of 14 |
| CS16-Volanesorsen | 0 of 3 |
Other (non-serious) adverse events
Participants with at least one non-serious event at or above the registry's 5% reporting threshold.
| Arm | Participants affected of at risk |
|---|---|
| Treatment-naïve Group | 51 of 51 |
| CS6-Volanesorsen | 14 of 14 |
| CS16-Volanesorsen | 3 of 3 |
Most frequent serious adverse event terms
| Event term | Organ system | Treatment-naïve Group | CS6-Volanesorsen | CS16-Volanesorsen |
|---|---|---|---|---|
| Thrombocytopenia | Blood and lymphatic system disorders | 3 of 51 | 0 of 14 | 1 of 3 |
| Pancreatitis | Gastrointestinal disorders | 2 of 51 | 0 of 14 | 0 of 3 |
| Pancreatitis acute | Gastrointestinal disorders | 2 of 51 | 0 of 14 | 0 of 3 |
| Pancreatitis chronic | Gastrointestinal disorders | 0 of 51 | 0 of 14 | 1 of 3 |
| Arthritis | Musculoskeletal and connective tissue disorders | 1 of 51 | 0 of 14 | 0 of 3 |
| Intervertebral disc protrusion | Musculoskeletal and connective tissue disorders | 1 of 51 | 0 of 14 | 0 of 3 |
| Myalgia | Musculoskeletal and connective tissue disorders | 0 of 51 | 1 of 14 | 0 of 3 |
| Tendon calcification | Musculoskeletal and connective tissue disorders | 1 of 51 | 0 of 14 | 0 of 3 |
| Influenza like illness | General disorders | 1 of 51 | 0 of 14 | 0 of 3 |
| Diverticulitis | Infections and infestations | 1 of 51 | 0 of 14 | 0 of 3 |
Most frequent non-serious adverse event terms
| Event term | Organ system | Treatment-naïve Group | CS6-Volanesorsen | CS16-Volanesorsen |
|---|---|---|---|---|
| Injection site erythema | General disorders | 36 of 51 | 7 of 14 | 1 of 3 |
| Nasopharyngitis | Infections and infestations | 21 of 51 | 4 of 14 | 0 of 3 |
| Injection site pain | General disorders | 21 of 51 | 3 of 14 | 0 of 3 |
| Abdominal pain | Gastrointestinal disorders | 14 of 51 | 5 of 14 | 3 of 3 |
| Injection site swelling | General disorders | 14 of 51 | 5 of 14 | 0 of 3 |
| Platelet count decreased | Investigations | 15 of 51 | 2 of 14 | 0 of 3 |
| Nausea | Gastrointestinal disorders | 11 of 51 | 4 of 14 | 1 of 3 |
| Headache | Nervous system disorders | 12 of 51 | 4 of 14 | 0 of 3 |
| Injection site pruritus | General disorders | 11 of 51 | 4 of 14 | 0 of 3 |
| Injection site discolouration | General disorders | 12 of 51 | 1 of 14 | 1 of 3 |
Serious events with the highest arm-level rate: pancreatitis chronic (33.3%), thrombocytopenia (33.3%), clavicle fracture (33.3%), myalgia (7.1%), focal segmental glomerulosclerosis (7.1%).
The registry reports serious adverse event counts by group. In Treatment-naïve Group, 13 of 51 participants at risk were affected; in CS6-Volanesorsen, 2 of 14 were affected; and in CS16-Volanesorsen, 2 of 3 were affected. The registry reports 0 deaths in each group. These are descriptive counts during the study, not estimates from a randomized comparison. The groups have different prior treatment histories, and the smallest group has only 3 participants at risk.
The registry also lists serious-event terms with percentages: Pancreatitis chronic (33.3%), Thrombocytopenia (33.3%), Clavicle fracture (33.3%), Myalgia (7.1%), Focal segmental glomerulosclerosis (7.1%), and Pancreatitis (3.9%). The record does not clearly identify a group assignment for each listed term in the information available, so those percentages should not be attributed to a particular group. The denominators and event-specific counts behind these percentages are not reported in the registry record.
Other adverse events affected 51 of 51 participants in Treatment-naïve Group, 14 of 14 in CS6-Volanesorsen, and 3 of 3 in CS16-Volanesorsen. Counts of affected participants do not describe event severity, duration, or causal relationship to treatment. The registry safety record alone cannot establish whether an event was caused by volanesorsen, and the non-randomized design does not support a like-for-like safety comparison across groups.
12. What the Result Does, and Does Not, Mean
The registry establishes what the primary outcome was intended to measure: mean percent change from baseline in fasting TG at Months 3, 6, and 12. It also gives the definitions used to construct baseline and follow-up values, identifies the analysis population, and describes the study as Phase 3, open-label, non-randomized, and parallel. These details clarify the question asked and the context in which observations were collected.
But the registry record does not report numerical estimates for the primary endpoint. It therefore does not establish the observed direction or magnitude of change, how much participants varied, or how precisely a mean was estimated. No conclusion about an endpoint difference or its statistical significance can be drawn from the endpoint information in this record. The endpoint definition is not itself a result.
Even if within-group changes were reported, they would describe change among participants who contributed data, rather than by themselves establishing what caused that change. As a general principle, a non-randomized study without a comparable concurrent control group cannot separate treatment effects from other explanations as effectively as a randomized comparison can. Here, the rollover groups had previously received volanesorsen, while the treatment-naïve group included participants with a different study history. The registry explicitly cautions that these arms are not a like-for-like control comparison.
The safety counts describe affected participants and deaths recorded for each group. They do not provide a causal attribution for events or a randomized comparative safety estimate. The serious-event term percentages also lack clearly identified group assignments in the record. These limits matter when reading the safety information alongside the absent primary endpoint estimates.
Thus, the registry supports a description of study design, endpoint construction, population definition, and listed safety counts. It does not support a quantitative account of primary endpoint response or a causal claim about treatment effect. Detailed statistical methods, missing-data procedures, and numerical endpoint results are not reported in the registry record.
13. Why This Trial Matters Statistically
This study is statistically informative in part because it illustrates how treatment history shapes the meaning of a group summary. Participants in the rollover groups had received volanesorsen in index studies, while the treatment-naïve group combined participants in the new study with participants who had received placebo in index studies. A mean change across these groups would therefore need to be read in light of those differing histories, not as a randomized comparison.
The endpoint definition is also detailed. Baseline is constructed differently for treatment-naïve and rollover participants, and the follow-up values at Months 3, 6, and 12 are defined using averages of nearby fasting assessments. These rules matter because an endpoint depends not only on the name of the measurement but also on how its baseline, follow-up timing, and analysis population are specified.
At the same time, the record highlights the difference between a well-defined outcome and a reported result. The primary outcome is clearly named and its timing is described, yet numerical outcome estimates and the analysis methods are not reported in the registry record. Readers cannot assess the observed change, its variability, or its precision from those definitions alone. This is a useful reminder that registry entries may contain substantial design detail without enough outcome information to evaluate an effect estimate.
The safety record likewise calls for attention to denominators. The at-risk groups are not the same size, and the CS16-Volanesorsen group includes 3 participants at risk. Counts are essential context for interpreting the reported serious adverse events, but they do not turn the groups into comparative controls. The registry’s warning that these arms are not like-for-like comparisons is central to a statistically careful reading.
14. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The most important limitation for interpreting the primary outcome is that numerical results are not reported in the registry record. Although the endpoint, time points, summary type, and population definition are described, the record does not provide the mean percent changes, standard deviations, confidence intervals, or p-values. The endpoint’s observed magnitude, direction, and precision therefore cannot be evaluated.
The design is non-randomized and open-label, with groups that differ in prior treatment history. The registry itself states that the arms are not a like-for-like control comparison. Comparisons between groups would be vulnerable to differences in participant characteristics or history that are not described in the record. No adjustment strategy is reported in the registry record.
The FAS definition requires enrollment, at least one dose, and a baseline TG assessment. The number analyzed is defined as those evaluable at each time point, but time-specific analyzed counts are not reported in the registry record. Missing-data handling, reasons for missing assessments, and sensitivity analyses are also not reported in the registry record. Consequently, the effect of incomplete follow-up on the endpoint cannot be assessed.
The registry lists 0 analyses and does not describe the statistical model, repeated-measure handling, covariates, or multiplicity strategy. It also does not report the protocol’s sample-size justification. Safety counts are descriptive, the smallest group has 3 participants at risk, and the listed serious-event term percentages are not clearly assigned to groups. These limitations constrain both outcome interpretation and comparisons across groups.
15. Related Tutorials
16. Related Statistical Calculators
17. Sources
- ClinicalTrials.gov: The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome — NCT02658175.
- Registry record last updated 2021-08-26; status last verified 2021-08.
- Results first posted 2021-08-26.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
18. Record Summary
The registry describes a completed Phase 3, open-label, non-randomized, parallel study of subcutaneous volanesorsen in participants with familial chylomicronemia syndrome. Enrollment was 68. The listed groups were Treatment-naïve Group, CS6-Volanesorsen, and CS16-Volanesorsen; the rollover groups had previously received volanesorsen.
The primary endpoint was mean percent change from baseline in fasting TG at Months 3, 6, and 12, summarized as a mean and standard deviation. The registry defines baseline and follow-up assessment construction but does not report numerical primary endpoint estimates or analyses. Safety counts include serious adverse events affecting 13 of 51, 2 of 14, and 2 of 3 participants across the three groups, respectively, with 0 deaths in each group. The registry cautions that the arms are not a like-for-like control comparison.